CONMED Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
CONMED wird ein jährliches Gewinn- und Umsatzwachstum von 27.7% bzw. 7.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.9% betragen.
Wichtige Informationen
23.8%
Wachstumsrate der Gewinne
24.0%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.5% |
| Wachstumsrate der Einnahmen | 7.0% |
| Zukünftige Eigenkapitalrendite | 14.8% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 25 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Why We're Not Concerned About CONMED Corporation's (NYSE:CNMD) Share Price
Sep 12
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
Aug 15CONMED Corporation's (NYSE:CNMD) Intrinsic Value Is Potentially 97% Above Its Share Price
Jul 17AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation
Jun 21There Is A Reason CONMED Corporation's (NYSE:CNMD) Price Is Undemanding
Jun 01Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching
Apr 18Is CONMED (NYSE:CNMD) Using Too Much Debt?
Mar 28CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26%
Feb 15US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results
Feb 03Should You Investigate CONMED Corporation (NYSE:CNMD) At US$107?
Jan 08Investors Appear Satisfied With CONMED Corporation's (NYSE:CNMD) Prospects
Dec 18CONMED (NYSE:CNMD) Takes On Some Risk With Its Use Of Debt
Nov 30Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business
Oct 28Is CONMED Corporation (NYSE:CNMD) Potentially Undervalued?
Sep 22Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?
Aug 24Conmed: Reiterate Buy Rating As Earnings Are Expected To Grow Strongly
Jul 28Should You Think About Buying CONMED Corporation (NYSE:CNMD) Now?
Jun 08These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Extensively
May 17Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)
Apr 28Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching
Mar 10Here's Why CONMED (NYSE:CNMD) Has A Meaningful Debt Burden
Feb 14CONMED Non-GAAP EPS of $0.42 misses by $0.48, revenue of $250.9M misses by $51.58M
Feb 02Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)
Jan 24ConMed: Still Fairly Priced, Turning More Constructive
Dec 09At US$83.60, Is CONMED Corporation (NYSE:CNMD) Worth Looking At Closely?
Nov 18Conmed withdraws FY22 guidance on software implementation-related disruption
Nov 15CONMED (NYSE:CNMD) Has A Pretty Healthy Balance Sheet
Oct 11ConMed: Fairly Priced At Pre-Pandemic Market Cap
Sep 21CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20
Sep 03CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20
Aug 18CONMED declares $0.20 dividend
Aug 11Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,514 | 175 | 196 | 192 | 7 |
| 12/31/2025 | 1,411 | 141 | 188 | 160 | 8 |
| 12/31/2024 | 1,308 | 108 | 137 | 130 | 8 |
| 6/30/2024 | 1,276 | 99 | 159 | 175 | N/A |
| 3/31/2024 | 1,262 | 82 | 142 | 158 | N/A |
| 12/31/2023 | 1,245 | 64 | 106 | 125 | N/A |
| 9/30/2023 | 1,169 | 58 | 38 | 57 | N/A |
| 6/30/2023 | 1,139 | 88 | 16 | 37 | N/A |
| 3/31/2023 | 1,099 | -94 | 7 | 29 | N/A |
| 12/31/2022 | 1,045 | -81 | 12 | 33 | N/A |
| 9/30/2022 | 1,069 | -83 | 59 | 79 | N/A |
| 6/30/2022 | 1,042 | -114 | 56 | 74 | N/A |
| 3/31/2022 | 1,020 | 68 | 74 | 90 | N/A |
| 12/31/2021 | 1,011 | 63 | 97 | 112 | N/A |
| 9/30/2021 | 989 | 62 | 83 | 98 | N/A |
| 6/30/2021 | 979 | 54 | 99 | 112 | N/A |
| 3/31/2021 | 881 | 13 | 70 | 83 | N/A |
| 12/31/2020 | 862 | 10 | 52 | 65 | N/A |
| 9/30/2020 | 874 | 0 | 69 | 85 | N/A |
| 6/30/2020 | 870 | 0 | 69 | 87 | N/A |
| 3/31/2020 | 951 | 34 | 84 | 103 | N/A |
| 12/31/2019 | 955 | 29 | 75 | 95 | N/A |
| 9/30/2019 | 933 | 29 | 60 | 79 | N/A |
| 6/30/2019 | 901 | 28 | 28 | 47 | N/A |
| 3/31/2019 | 876 | 31 | 29 | 46 | N/A |
| 12/31/2018 | 860 | 41 | 58 | 75 | N/A |
| 9/30/2018 | 840 | 72 | 55 | 71 | N/A |
| 6/30/2018 | 828 | 73 | 65 | 80 | N/A |
| 3/31/2018 | 812 | 71 | N/A | 75 | N/A |
| 12/31/2017 | 796 | 55 | N/A | 66 | N/A |
| 9/30/2017 | 778 | 15 | N/A | 58 | N/A |
| 6/30/2017 | 773 | 16 | N/A | 70 | N/A |
| 3/31/2017 | 769 | 12 | N/A | 72 | N/A |
| 12/31/2016 | 764 | 15 | N/A | 40 | N/A |
| 9/30/2016 | 750 | 16 | N/A | 36 | N/A |
| 6/30/2016 | 735 | 17 | N/A | 24 | N/A |
| 3/31/2016 | 722 | 22 | N/A | 17 | N/A |
| 12/31/2015 | 719 | 30 | N/A | 51 | N/A |
| 9/30/2015 | 723 | 34 | N/A | 64 | N/A |
| 6/30/2015 | 729 | 27 | N/A | 65 | N/A |
| 3/31/2015 | 736 | 30 | N/A | 63 | N/A |
| 12/31/2014 | 740 | 32 | N/A | 65 | N/A |
| 9/30/2014 | 747 | 31 | N/A | 67 | N/A |
| 6/30/2014 | 750 | 35 | N/A | 83 | N/A |
| 3/31/2014 | 753 | 34 | N/A | 93 | N/A |
| 12/31/2013 | 763 | 36 | N/A | 81 | N/A |
| 9/30/2013 | 756 | 37 | N/A | 88 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CNMDDas prognostizierte Gewinnwachstum (27.7% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: CNMDDie Erträge des Unternehmens (27.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).
Hohe Wachstumserträge: CNMDEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: CNMDDie Einnahmen des Unternehmens (7.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: CNMDDie Einnahmen des Unternehmens (7.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: CNMDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.9%).